TELK -- Telik, Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : TELK -- Telik, Inc.

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Icebrg	6/6/2007 1:14:17 AM
	of 887

According to Dr. Michael Bookman, an oncologist at Fox Chase Cancer Center who participated in an early stage trial of Telcyta, Telik's ambition and the enormous pressure to succeed may have clouded its judgement. During the early trial, Bookman wanted to take tissue samples of the patients in order to understand whether the drug was more effective in patients with certain enzyme characteristics. However, the company refused his request "because it might have potentially complicated regulatory filings," Bookman said. The study would have been expensive and the findings may have restricted the drug's usage, damaging its marketablity. "I think it was a shame they chose not to go down the path of getting more data, it would have helped them guide their study more carefully," Bookman said. forbes.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next